降糖药物与糖尿病患者COVID-19住院前结局的关联:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入31项观察性研究、共3 689 010例因COVID-19住院的糖尿病患者,评估8种降糖药物与COVID-19相关不良结局(ICU入住、有创或无创机械通气或院内死亡)的关联。贝叶斯网络Meta分析显示,SGLT-2i相比胰岛素(logOR 0.91;95%CrI 0.57-1.26)、DPP-4i(logOR 0.61;95%CrI 0.28-0.93)、促泌剂(logOR 0.37;95%CrI 0.02-0.72)和糖苷酶抑制剂(logOR 0.50;95%CrI 0.00-1.01)与相对较低的不良结局风险相关。基于累积排序曲线下面积,SGLT-2i与最低的不良结局概率相关(6%),其次为GLP-1RA(25%)和二甲双胍(28%)。敏感性分析显示研究可靠。
要点
- 糖尿病患者在COVID-19住院前使用SGLT-2i与较低的不良结局风险相关,优于胰岛素、DPP-4i、促泌剂和糖苷酶抑制剂。
- 基于累积排序曲线下面积,SGLT-2i与最低的不良结局概率相关(6%),其次为GLP-1RA(25%)和二甲双胍(28%)。
- SGLT-2i相比胰岛素的logOR为0.91(95%CrI 0.57-1.26),相比DPP-4i为0.61(95%CrI 0.28-0.93),相比促泌剂为0.37(95%CrI 0.02-0.72),相比糖苷酶抑制剂为0.50(95%CrI 0.00-1.01)。
- 该分析纳入31项观察性研究,共3 689 010例因COVID-19住院的糖尿病患者。
适用人群与场景
- 糖尿病患者,在确诊COVID-19感染前接受降糖治疗至少14天,后因COVID-19住院。
研究设计与关键结果
- 系统评价与网络Meta分析纳入31项观察性研究,共3 689 010例因COVID-19住院的糖尿病患者。
- SGLT-2i相比胰岛素与相对较低的不良结局风险相关(logOR 0.91;95%CrI 0.57-1.26)。
- SGLT-2i相比DPP-4i与相对较低的不良结局风险相关(logOR 0.61;95%CrI 0.28-0.93)。
- SGLT-2i相比促泌剂与相对较低的不良结局风险相关(logOR 0.37;95%CrI 0.02-0.72)。
- SGLT-2i相比糖苷酶抑制剂与相对较低的不良结局风险相关(logOR 0.50;95%CrI 0.00-1.01)。
- 基于累积排序曲线下面积,SGLT-2i与最低的不良结局概率相关(6%),其次为GLP-1RA(25%)和二甲双胍(28%)。
- 敏感性分析显示研究可靠。
证据类型、等级与局限
- 证据类型:系统评价与网络Meta分析,纳入随机临床试验和观察性研究,最终分析31项观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,COVID-19感染前使用SGLT-2i与较低的COVID-19相关不良结局相关。
- 作者认为,除SGLT-2i外,GLP-1RA和二甲双胍也与相对较低的不良结局风险相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with COVID-19 have a high prevalence of diabetes, and diabetes and blood glucose control are determinants of intensive care unit admission and mortality.
OBJECTIVE: To evaluate the association between COVID-19-related adverse outcomes and 8 antihyperglycemic drugs in patients with diabetes who were subsequently diagnosed and hospitalized with COVID-19.
DATA SOURCES: Data were retrieved and collected in PubMed, Embase, Cochrane Central Register, Web of Science, and ClinicalTrials.gov from database inception to September 5, 2022.
STUDY SELECTION: For this systematic review and network meta-analysis, randomized clinical trials and observational studies conducted among patients with diabetes while receiving glucose-lowering therapies for at least 14 days before the confirmation of COVID-19 infection were included after blinded review by 2 independent reviewers and consultations of disagreement by a third independent reviewer. Of 1802 studies initially identified, 31 observational studies met the criteria for further analysis.
DATA EXTRACTION AND SYNTHESIS: This study follows the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline. Bayesian network meta-analyses were performed with random effects.
MAIN OUTCOMES AND MEASURES: A composite adverse outcome, including the need for intensive care unit admission, invasive and noninvasive mechanical ventilation, or in-hospital death.
RESULTS: Thirty-one distinct observational studies (3 689 010 patients with diabetes hospitalized for COVID-19) were included. The sodium-glucose cotransporter-2 inhibitors (SGLT-2is) were associated with relatively lower risks of adverse outcomes compared with insulin (log of odds ratio [logOR], 0.91; 95% credible interval [CrI], 0.57-1.26), dipeptidyl peptidase-4 inhibitors (logOR, 0.61; 95% CrI, 0.28-0.93), secretagogues (logOR, 0.37; 95% CrI, 0.02-0.72), and glucosidase inhibitors (logOR, 0.50; 95% CrI, 0.00-1.01). Based on the surface under the cumulative ranking curves value, SGLT-2is were associated with the lowest probability for adverse outcomes (6%), followed by glucagon-like peptide-1 receptor agonists (25%) and metformin (28%). A sensitivity analysis revealed that the study was reliable.
CONCLUSIONS AND RELEVANCE: These findings suggest that the use of an SGLT-2i before COVID-19 infection is associated with lower COVID-19-related adverse outcomes. In addition to SGLT-2is, glucagon-like peptide-1 receptor agonists and metformin were also associated with relatively low risk of adverse outcomes.
参考来源
- Zhu Z, Zeng Q, Liu Q, et al. Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2022. PMID: 36472874. doi:10.1001/jamanetworkopen.2022.44652
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。